BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9258804)

  • 1. Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.
    Giusti M; Foppiani L; Ponzani P; Cuttica CM; Falivene MR; Valenti S
    J Endocrinol Invest; 1997 May; 20(5):257-63. PubMed ID: 9258804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
    Popovic V; Micic D; Djurovic M; Obradovic S; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1997 May; 46(5):539-43. PubMed ID: 9231048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.
    De Marinis L; Mancini A; Valle D; Izzi D; Bianchi A; Gentilella R; Giampietro A; Desenzani P; Giustina A
    Horm Metab Res; 2000 Apr; 32(4):152-6. PubMed ID: 10824712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.
    Loche S; Cambiaso P; Merola B; Colao A; Faedda A; Imbimbo BP; Deghenghi R; Lombardi G; Cappa M
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2692-6. PubMed ID: 7673411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa.
    De Marinis L; Mancini A; Valle D; Bianchi A; Gentilella R; Milardi D; Mascadri C; Giustina A
    Metabolism; 2000 Feb; 49(2):155-9. PubMed ID: 10690937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
    Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
    Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
    Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
    Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.